A

Alexion

Global biopharmaceuticals focusing on rare diseases

Regional Sales Director - Multiple Teams

Full-Time
No salary listed
Expert
Bachelor's, Master's
Richmond, VA, USA
HybridResidence must be within close proximity to the Mid-Atlantic region; regular travel, including frequent overnight and occasional weekend travel, is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree in life sciences, business, marketing, or a related discipline.
  • A sustained record of building leadership capability, developing talent, managing performance, and creating teams that consistently deliver.
  • At least 10 years of progressive experience in pharmaceuticals, biotechnology, medical devices, or an equivalent healthcare environment.
  • Leadership experience with manager-level talent and above, with the ability to lead through other leaders and deliver results across a complex region.
  • Specialty commercial experience engaging neurologists, neuro-immunologists, or other highly specialized customers.
  • Demonstrated success scaling or significantly expanding sales teams while protecting culture, performance standards, and customer continuity.
  • Broad commercial perspective gained through partnership with, or experience in, functions such as Marketing, Sales Operations, Medical, National or Corporate Accounts, Managed Markets, and Hospital Markets.
  • Experience leading through the complexity, pace, and cross-functional demands of a biopharmaceutical launch.
  • A valid driver's license and a driving record that meets company requirements.
  • Residence within close proximity to the Mid-Atlantic region and flexibility to travel regularly, including frequent overnight and occasional weekend travel.
  • Ability to travel by public transportation, automobile, train, or plane; work comfortably in a clinical setting; use a computer; communicate by phone, video, and electronic messaging; solve problems; engage in complex and non-linear thought, analysis, and dialogue; collaborate with others; and maintain general availability during standard business hours.
Responsibilities
  • Set the commercial direction for a high-impact Mid-Atlantic region, translating national Neurology strategy into focused execution that meets or exceeds sales objectives.
  • Lead, coach, and develop a team of 7–8 Regional Account Managers, providing clarity, accountability, and development experiences.
  • Use knowledge of rare-disease markets, local health systems, practice structures, and key influencers to establish regional priorities and provide market insight to senior commercial leaders.
  • Use performance analytics, customer insights, and business judgment to identify growth opportunities, anticipate barriers, and deploy people and resources effectively.
  • Partner with Regional Account Managers to build locally relevant business plans and customer strategies that advance disease, diagnostic, and branded education compliantly and ethically.
  • Attract talent, retain critical capabilities, strengthen succession pipelines, and accelerate the growth of current and future leaders.
  • Maintain a visible field presence through customer visits and business reviews, providing coaching to strengthen commercial performance and career development.
  • Build relationships with physicians, thought leaders, and health-system stakeholders to understand unmet needs and improve customer experience.
  • Guide the team in opening new accounts, expanding existing partnerships, and navigating complex access and stakeholder environments across the region.
  • Set expectations for clinical acumen, business acumen, customer engagement, and execution in interactions with customers.
  • Coordinate with Sales, Marketing, Medical, Market Access, Operations, and other partners to translate enterprise strategy into regional action.
  • Design and lead Plan of Action meetings to sharpen strategic choices, strengthen team capability, and sustain execution momentum.
  • Translate regional insights into enterprise opportunities and influence US brand strategy for the Neurology therapeutic area.
  • Engage with the VP/Business Unit Lead and senior leadership through business reviews focused on growth, organizational health, talent, and corporate objectives.
  • Ensure decisions and activities comply with applicable laws, internal policies, and the Code of Ethics and Business Conduct.
Desired Qualifications
  • Orphan-drug sales or launch experience is strongly valued.
  • An advanced or master's degree.
  • Bio/pharmaceutical leadership experience in Neurology and/or Ophthalmology, particularly in markets with complex diagnostic and referral pathways.
  • Rare-disease commercial leadership experience, including buy-and-bill, hospital, health-system, access, or similarly complex account environments.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old